GlassScriptPhysician profile
Debra Lynn Moore
NPI 1750630497
$3,190.45
in general payments reported to CMS, 2019-2025
18 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 90% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.47 · 2022: $118 · 2023: $644 · 2024: $956 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,993 · Education: $16.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,993.18 |
| Education | $16.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,357.84 | 2022-2025 | |
| Janssen Biotech, INC. | $333.01 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Lilly USA, LLC | $229.95 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $226.27 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $220.58 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $197.04 | 2023-2025 | Entyvio, Eohilia |
| Pfizer INC. | $108.54 | 2024-2025 | |
| Madrigal Pharmaceuticals | $90.75 | 2025 | Rezdiffra |
| Ardelyx, INC. | $85.06 | 2023 | Ibsrela |
| Aimmune Therapeutics, INC. | $72.06 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.44 | 2025 | Xifaxan |
| Braintree Laboratories, INC. | $47.99 | 2024-2025 | Suflave |
| Regeneron Healthcare Solutions, INC. | $35.72 | 2024 | Dupixent |
| Genzyme Corporation | $35.24 | 2025 | |
| Axonics, INC. | $32.41 | 2023 | Axonics |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $27.67 | 2025 | Injectafer |
| Novo Nordisk INC | $23.03 | 2025 | Wegovy |
| Celltrion USA INC. | $16.85 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.